The Herceptin drug, produced by La Roche, is showing promise of decreasing cancer recurrence, according to a new study published in The Lancet Oncology.
The study looked at 5,000 women who had been diagnosed with breast cancer between 2001 and 2005, with results indicating a 24 percent less chance of cancer return in those who took Herceptin, also known as trastuzumab, reported U.S. News.
According to The Telegraph, a British woman named Ann Marie Rogers sued and won a case to receive Herceptin in 2006.
Adriana Jenkins, a famous breast cancer awareness
advocate who recently passed away, wrote a letter to Forbes in February urging personalized medicine, the method through which she received Herceptin.
Jenkins credited Herceptin for lengthening her life post-diagnosis by at least nine years, according to Forbes.
Herceptin works by suppressing the HER2/neu cancer-causing protein, according to U.S. News, and researchers are now looking into the long-term use of Herceptin.
"We were inclined to consider the possibility that long-term exposure to trastuzumab deserved a proper test and might be useful," Dr. Luca Gianni, of Milan's Fondazione San Raffaele, told the news source following the new studies.